Bedaquiline-a potential inhibitor of COVID-19 main protease based on molecular docking. International Journal of Research in Pharmacology & Pharmacotherapeutics, [S. l.], v. 9, n. 2, p. 136–144, 2021. DOI: 10.61096/ijrpp.v9.iss2.2020.136-144. Disponível em: https://ijrpp.com/ijrpp/article/view/29. Acesso em: 17 apr. 2026.